<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39399167</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2234-943X</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials.</ArticleTitle><Pagination><StartPage>1454370</StartPage><MedlinePgn>1454370</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1454370</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2024.1454370</ELocationID><Abstract><AbstractText>Originally devised for cancer control, mRNA vaccines have risen to the forefront of medicine as effective instruments for control of infectious disease, notably their pivotal role in combating the COVID-19 pandemic. This review focuses on fundamental aspects of the development of mRNA vaccines, e.g., tumor antigens, vector design, and precise delivery methodologies, - highlighting key technological advances. The recent, promising success of personalized mRNA vaccines against pancreatic cancer and melanoma illustrates the potential value for other intractable, immunologically resistant, solid tumors, such as glioblastoma, as well as the potential for synergies with a combinatorial, immunotherapeutic approach. The impact and progress in human cancer, including pancreatic cancer, head and neck cancer, bladder cancer are reviewed, as are lessons learned from first-in-human CAR-T cell, DNA and dendritic cell vaccines targeting glioblastoma. Going forward, a roadmap is provided for the transformative potential of mRNA vaccines to advance cancer immunotherapy, with a particular focus on the opportunities and challenges of glioblastoma. The current landscape of glioblastoma immunotherapy and gene therapy is reviewed with an eye to combinatorial approaches harnessing RNA science. Preliminary preclinical and clinical data supports the concept that mRNA vaccines could be a viable, novel approach to prolong survival in patients with glioblastoma.</AbstractText><CopyrightInformation>Copyright © 2024 Tapescu, Madsen, Lowenstein, Castro, Bagley, Fan and Brem.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tapescu</LastName><ForeName>Iulia</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madsen</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurosurgery, Children's Hospital of Philadelphia, Philadelphia, PA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowenstein</LastName><ForeName>Pedro R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, The University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell and Developmental Biology, The University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, The University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>Maria G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, The University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell and Developmental Biology, The University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bagley</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brem</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">brain tumor</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">glioblastoma</Keyword><Keyword MajorTopicYN="N">glioma</Keyword><Keyword MajorTopicYN="N">immuno-oncology</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">mRNA</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>7</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39399167</ArticleId><ArticleId IdType="pmc">PMC11466887</ArticleId><ArticleId IdType="doi">10.3389/fonc.2024.1454370</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. (2005) 23:165–75. doi: 10.1016/j.immuni.2005.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2005.06.008</ArticleId><ArticleId IdType="pubmed">16111635</ArticleId></ArticleIdList></Reference><Reference><Citation>
Karikó K, Weissman D. RNA containing modified nucleosides and methods of use thereof. US Patent #9,750,824 B2 (9/5/2017) . Available online at: https://patents.google.com/patent/US9750824B2/ (Accessed September 4, 2024).</Citation></Reference><Reference><Citation>Laczkó D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, et al. . A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity. (2020) 53:724–32.e7. doi: 10.1016/j.immuni.2020.07.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.07.019</ArticleId><ArticleId IdType="pmc">PMC7392193</ArticleId><ArticleId IdType="pubmed">32783919</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. (2020) 383:2603–15. doi: 10.1056/NEJMoa2034577</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Buggert M, Höglund P. The prize of prizes: mRNA research paving the way for COVID-19 vaccine success wins the Nobel Prize in Physiology or Medicine 2023. Scand J Immunol. (2023) 98:e13340. doi: 10.1111/sji.13340</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.13340</ArticleId><ArticleId IdType="pubmed">37953432</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics – developing a new class of drugs. Nat Rev Drug Discovery. (2014) 13:759–80. doi: 10.1038/nrd4278</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4278</ArticleId><ArticleId IdType="pubmed">25233993</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, et al. . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. (2020) 585:107–12. doi: 10.1038/s41586-020-2537-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2537-9</ArticleId><ArticleId IdType="pubmed">32728218</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. (2021) 384:403–16. doi: 10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. . COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. (2020) 586:594–99. doi: 10.1038/s41586-020-2814-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2814-7</ArticleId><ArticleId IdType="pubmed">32998157</ArticleId></ArticleIdList></Reference><Reference><Citation>Bidram M, Zhao Y, Shebardina NG, Baldin AV, Bazhin AV, Ganjalikhany MR, et al. . mRNA-based cancer vaccines: A therapeutic strategy for the treatment of melanoma patients. Vaccines. (2021) 9:1060. doi: 10.3390/vaccines9101060</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9101060</ArticleId><ArticleId IdType="pmc">PMC8540049</ArticleId><ArticleId IdType="pubmed">34696168</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber J, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. . Individualized therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomized, phase 2b study. Lancet. (2024) 403:632–44. doi: 10.1016/S0140-6736(23)02268-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)02268-7</ArticleId><ArticleId IdType="pubmed">38246194</ArticleId></ArticleIdList></Reference><Reference><Citation>Kübler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, et al. . Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer. (2015) 3:26. doi: 10.1186/s40425-015-0068-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-015-0068-y</ArticleId><ArticleId IdType="pmc">PMC4468959</ArticleId><ArticleId IdType="pubmed">26082837</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahnazari M, Samadi P, Pourjafar M, Jalali A. Therapeutic vaccines for colorectal cancer: The progress and future prospect. Int Immunopharmacol. (2020) 88:106944. doi: 10.1016/j.intimp.2020.106944</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.106944</ArticleId><ArticleId IdType="pubmed">33182032</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R. mRNA cancer vaccines. Recent Results Cancer Res. (2016) 209:61–85. doi: 10.1007/978-3-319-42934-2_5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-42934-2_5</ArticleId><ArticleId IdType="pubmed">28101688</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez-Gomez HR, DeVries A, Castillo P, von Roemeling C, Qdaisat S, Stover BD, et al. . RNA aggregates harness the danger response for potent cancer immunotherapy. Cell. (2024) 187:2521–35. doi: 10.1016/j.cell.2024.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2024.04.003</ArticleId><ArticleId IdType="pubmed">38697107</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discovery. (2018) . 17:261–79. doi: 10.1038/nrd.2017.243</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.243</ArticleId><ArticleId IdType="pmc">PMC5906799</ArticleId><ArticleId IdType="pubmed">29326426</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu D, Petsch B. Preface to mRNA vaccines. Curr Top Microbiol Immunol. (2022) 440:viii. doi: 10.1007/978-3-031-18070-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-031-18070-5</ArticleId><ArticleId IdType="pubmed">33591423</ArticleId></ArticleIdList></Reference><Reference><Citation>Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book. (2019) 39:147–64. doi: 10.1200/EDBK_240837</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/EDBK_240837</ArticleId><ArticleId IdType="pubmed">31099674</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuchter LM. Adjuvant melanoma therapy – Head-spinning progress. N Engl J Med. (2017) 377:1888–90. doi: 10.1056/NEJMe1711199</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe1711199</ArticleId><ArticleId IdType="pubmed">29117487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu A, Lim M. Advancing combination therapy for recurrent glioblastoma. Nat Med. (2023) 29:1318–9. doi: 10.1038/s41591-023-02350-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02350-3</ArticleId><ArticleId IdType="pubmed">37188784</ArticleId></ArticleIdList></Reference><Reference><Citation>Uslu U, Castelli S, June CH. CAR T cell combination therapies to treat cancer. Cancer Cell. (2024) 42:1319–25. doi: 10.1016/j.ccell.2024.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2024.07.002</ArticleId><ArticleId IdType="pubmed">39059390</ArticleId></ArticleIdList></Reference><Reference><Citation>Datsi A, Sorg RV. Dendritic cell vaccination of glioblastoma: Road to success or dead end. Front Immunol. (2021) 12:770390. doi: 10.3389/fimmu.2021.770390</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.770390</ArticleId><ArticleId IdType="pmc">PMC8592940</ArticleId><ArticleId IdType="pubmed">34795675</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. (2022) 15:28. doi: 10.1186/s13045-022-01247-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-022-01247-x</ArticleId><ArticleId IdType="pmc">PMC8931585</ArticleId><ArticleId IdType="pubmed">35303904</ArticleId></ArticleIdList></Reference><Reference><Citation>van Solinge TS, Nieland L, Chiocca EA, Broekman MLD. Advances in local therapy for glioblastoma—taking the fight to the tumour. Nat Rev Neurol. (2022) 18:221–36. doi: 10.1038/s41582-022-00621-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-022-00621-0</ArticleId><ArticleId IdType="pmc">PMC10359969</ArticleId><ArticleId IdType="pubmed">35277681</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsyth PA, Abate-Daga D. Oncolytic virotherapy for Malignant glioma. J Clin Oncol. (2018) 36:1440–2. doi: 10.1200/JCO.2017.77.3192</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2017.77.3192</ArticleId><ArticleId IdType="pubmed">29437534</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling AL, Solomon IH, Landivar AM, Nakashima H, Woods JK, Santos A, et al. . Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature. (2023) 623:157–66. doi: 10.1038/s41586-023-06623-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06623-2</ArticleId><ArticleId IdType="pmc">PMC10620094</ArticleId><ArticleId IdType="pubmed">37853118</ArticleId></ArticleIdList></Reference><Reference><Citation>Raimondo TM, Reed K, Shi D, Langer R, Anderson DG. Delivering the next generation of cancer immunotherapies with RNA. Cell. (2023) 186:1535–40. doi: 10.1016/j.cell.2023.02.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.02.031</ArticleId><ArticleId IdType="pubmed">37059063</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemente B, Denis M, Silveira CP, Schiavetti F, Brazzoli M, Stranges D. Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design. Front Immunol. (2023) 14:1294929. doi: 10.3389/fimmu.2023.1294929</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1294929</ArticleId><ArticleId IdType="pmc">PMC10711611</ArticleId><ArticleId IdType="pubmed">38090568</ArticleId></ArticleIdList></Reference><Reference><Citation>Dain L, Zhu G. Nucleic acid immunotherapeutics and vaccines: A promising approach to glioblastoma multiforme treatment. Int J Pharm. (2023) 638:11294. doi: 10.1016/j.ijpharm.2023.122924</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2023.122924</ArticleId><ArticleId IdType="pmc">PMC10194422</ArticleId><ArticleId IdType="pubmed">37037396</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang F, Schrörs B, Löwer M, Türeci O, Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discovery. (2022) 21:261–82. doi: 10.1038/s41573-021-00387-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-021-00387-y</ArticleId><ArticleId IdType="pmc">PMC7612664</ArticleId><ArticleId IdType="pubmed">35105974</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayour EJ, Boczkowski D, Mitchell DA, Nair SK. Cancer mRNA vaccines: clinical advances and future opportunities. Nat Rev Clin Oncol. (2024) 21:489–500. doi: 10.1038/s41571-024-00902-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-024-00902-1</ArticleId><ArticleId IdType="pubmed">38760500</ArticleId></ArticleIdList></Reference><Reference><Citation>Melnick K, Dastmalchi F, Mitchell D, Rahman M, Sayour EJ. Contemporary RNA therapeutics for glioblastoma. Neuromol Med. (2022) 24:8–12. doi: 10.1007/s12017-021-08669-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-021-08669-9</ArticleId><ArticleId IdType="pmc">PMC8186014</ArticleId><ArticleId IdType="pubmed">34101090</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman MM, Zhou N, Huang J. An overview on the development of mRNA-based vaccines and their formulation strategies for improved antigen expression in vivo . Vaccines. (2021) 9:244. doi: 10.3390/vaccines9030244</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9030244</ArticleId><ArticleId IdType="pmc">PMC8001631</ArticleId><ArticleId IdType="pubmed">33799516</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. (2023) 8:450. doi: 10.1038/s41392-023-01674-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01674-3</ArticleId><ArticleId IdType="pmc">PMC10716479</ArticleId><ArticleId IdType="pubmed">38086815</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes A, Bastiancich C, Bausart M, Ligot S, Lambricht L, Vanvarenberg K, et al. . New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models. J Immunother Cancer. (2021) 9:e001243. doi: 10.1136/jitc-2020-001243</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-001243</ArticleId><ArticleId IdType="pmc">PMC8021892</ArticleId><ArticleId IdType="pubmed">33795383</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik R, Peden K. Regulatory consideration on the development of mRNA vaccines. Curr Top Microbiol Immunol. (2022) 440:187–205. doi: 10.1007/82_2020_220</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/82_2020_220</ArticleId><ArticleId IdType="pubmed">32638114</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J, Hui AM. The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines. Cancer Treat Rev. (2022) 107:102405. doi: 10.1016/j.ctrv.2022.102405</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2022.102405</ArticleId><ArticleId IdType="pmc">PMC9068246</ArticleId><ArticleId IdType="pubmed">35576777</ArticleId></ArticleIdList></Reference><Reference><Citation>Domchek SM, Vonderheide RH. Advancing cancer interception. Cancer Discovery. (2024) 14:600–4. doi: 10.1158/2159-8290.CD-24-0015</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-24-0015</ArticleId><ArticleId IdType="pubmed">38571414</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagley S, Polley M-Y, Kotecha R, Brem S, Tolakanahalli R, Iwamoto F, et al. . A safety run-in and phase II study evaluating the combination of tocilizumab, atezolizumab, and fractionated stereotactic radiotherapy in recurrent glioblastoma – trial in progress. Neuro-Oncol. (2022) 24:vii64. doi: 10.1093/neuonc/noac209.253</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noac209.253</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhard K, Rengstl B, Oehm P, Michel K, Billmeier A, Hayduk N, et al. . An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. (2020) 367:446–53. doi: 10.1126/science.aay5967</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aay5967</ArticleId><ArticleId IdType="pubmed">31896660</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa-Carrasco G, Chiu E, Scrivo A, Zumbo P, Dave A, Betel D, et al. . Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell. (2024) 42:1202–16. doi: 10.1016/j.ccell.2024.05.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2024.05.025</ArticleId><ArticleId IdType="pmc">PMC11413804</ArticleId><ArticleId IdType="pubmed">38906155</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Yang K, Li R, Zhang L. mRNA vaccine era—mechanisms, drug platform and clinical prospection. Int J Mol Sci. (2020) 21:6582. doi: 10.3390/ijms21186582</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21186582</ArticleId><ArticleId IdType="pmc">PMC7554980</ArticleId><ArticleId IdType="pubmed">32916818</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, Duan J, Yang N, Yang Y, Zhao X. mRNA vaccines in the prevention and treatment of diseases. Med Comm. (2022) 3:e167. doi: 10.1002/mco2.167</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.167</ArticleId><ArticleId IdType="pmc">PMC9409637</ArticleId><ArticleId IdType="pubmed">36033422</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijkers GT, Weterings N, Obregon-Henao A, Lepolder M, Dutt TS, van Overveld FJ, et al. . Antigen presentation of mRNA-based and virus-vectored SARS-CoV-2 vaccines. Vaccines. (2021) 9:848. doi: 10.3390/vaccines9080848</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9080848</ArticleId><ArticleId IdType="pmc">PMC8402319</ArticleId><ArticleId IdType="pubmed">34451973</ArticleId></ArticleIdList></Reference><Reference><Citation>Murira A, Lamarre A. Type-I interferon responses: From friend to foe in the battle against viral infection. Front Immunol. (2016) 7:609. doi: 10.3389/fimmu.2016.00609</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00609</ArticleId><ArticleId IdType="pmc">PMC5165262</ArticleId><ArticleId IdType="pubmed">28066419</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Lu M, Qin Y, Gao W, Tao L, Su W, et al. . Neoantigen: A new breakthrough in tumor immunotherapy. Front Immunol. (2021) 12:672356. doi: 10.3389/fimmu.2021.672356</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.672356</ArticleId><ArticleId IdType="pmc">PMC8085349</ArticleId><ArticleId IdType="pubmed">33936118</ArticleId></ArticleIdList></Reference><Reference><Citation>Esprit A, de Mey W, Bahadur Shahi R, Thielemans K, Franceschini L, Breckpot K. Neo-antigen mRNA vaccines. Vaccines. (2020) 8:776. doi: 10.3390/vaccines8040776</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8040776</ArticleId><ArticleId IdType="pmc">PMC7766040</ArticleId><ArticleId IdType="pubmed">33353155</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjerregaard A-M, Nielsen M, Jurtz V, Barra CM, Hadrup SR, Szallasi Z, et al. . An analysis of natural T cell responses to predicted tumor neoepitopes. Front Immunol. (2017) 8:1566. doi: 10.3389/fimmu.2017.01566</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01566</ArticleId><ArticleId IdType="pmc">PMC5694748</ArticleId><ArticleId IdType="pubmed">29187854</ArticleId></ArticleIdList></Reference><Reference><Citation>Warminski M, Mamot A, Depaix A, Kowalska J, Jemielity J. Chemical modifications of mRNA ends for therapeutic applications. Acc Chem Res. (2023) 56:2814–26. doi: 10.1021/acs.accounts.3c00442</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.accounts.3c00442</ArticleId><ArticleId IdType="pmc">PMC10586375</ArticleId><ArticleId IdType="pubmed">37782471</ArticleId></ArticleIdList></Reference><Reference><Citation>Capietto A-H, Hoshyar R, Delamarre L. Sources of cancer neoantigens beyond single-nucleotide variants. Int J Mol Sci. (2022) 23:10131. doi: 10.3390/ijms231710131</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231710131</ArticleId><ArticleId IdType="pmc">PMC9455963</ArticleId><ArticleId IdType="pubmed">36077528</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, et al. . mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm. (2021) 601:120586. doi: 10.1016/j.ijpharm.2021.120586</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120586</ArticleId><ArticleId IdType="pmc">PMC8032477</ArticleId><ArticleId IdType="pubmed">33839230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. (2021) 28:117–29. doi: 10.1038/s41434-020-00204-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41434-020-00204-y</ArticleId><ArticleId IdType="pmc">PMC7580817</ArticleId><ArticleId IdType="pubmed">33093657</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakney AK, Ip S, Geall AJ. An update on self-amplifying mRNA vaccine development. Vaccines. (2021) 9:97. doi: 10.3390/vaccines9020097</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9020097</ArticleId><ArticleId IdType="pmc">PMC7911542</ArticleId><ArticleId IdType="pubmed">33525396</ArticleId></ArticleIdList></Reference><Reference><Citation>Witten J, Hu Y, Langer R, Anderson DG. Recent advances in nanoparticulate RNA delivery systems. Proc Natl Acad Sci. (2024) 121:e2307798120. doi: 10.1073/pnas.2307798120</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2307798120</ArticleId><ArticleId IdType="pmc">PMC10945842</ArticleId><ArticleId IdType="pubmed">38437569</ArticleId></ArticleIdList></Reference><Reference><Citation>Alameh M-G, Tombácz I, Bettini E, Lederer K, Ndeupen S, Sittplangkoon C, et al. . Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. (2021) 54:2877–92. e2877. doi: 10.1016/j.immuni.2021.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.11.001</ArticleId><ArticleId IdType="pmc">PMC8566475</ArticleId><ArticleId IdType="pubmed">34852217</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. (2021) 6:1078–94. doi: 10.1038/s41578-021-00358-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41578-021-00358-0</ArticleId><ArticleId IdType="pmc">PMC8353930</ArticleId><ArticleId IdType="pubmed">34394960</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Delivery. (2016) 7:319–34. doi: 10.4155/tde-2016-0006</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/tde-2016-0006</ArticleId><ArticleId IdType="pmc">PMC5439223</ArticleId><ArticleId IdType="pubmed">27075952</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu M, Tang Y, Chen J, Muriph R, Ye Z, Huang C, et al. . Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA. (2022) 119:e2116271119. doi: 10.1073/pnas.2116271119</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2116271119</ArticleId><ArticleId IdType="pmc">PMC8872770</ArticleId><ArticleId IdType="pubmed">35173043</ArticleId></ArticleIdList></Reference><Reference><Citation>Swingle KL, Safford HC, Geisler HC, Hamilton AG, Thatte AS, Billingsley MM, et al. . Ionizable lipid nanoparticles for in vivo mRNA delivery to the placenta during pregnancy. J Am Chem Soc. (2023) 145:4691–706. doi: 10.1021/jacs.2c12893</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.2c12893</ArticleId><ArticleId IdType="pmc">PMC9992266</ArticleId><ArticleId IdType="pubmed">36789893</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao L, Li L, Huang Y, Delcassian D, Chahal J, Han J, et al. . Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. (2019) 37:1174–85. doi: 10.1038/s41587-019-0247-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0247-3</ArticleId><ArticleId IdType="pubmed">31570898</ArticleId></ArticleIdList></Reference><Reference><Citation>Kon E, Ad-El N, Hazan-Halevy I, Stotsky-Oterin L, Peer D. Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects. Nat Rev Clin Oncol. (2023) 20:739–54. doi: 10.1038/s41571-023-00811-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-023-00811-9</ArticleId><ArticleId IdType="pubmed">37587254</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang A, Pressnall MM, Lu R, Huayamares SG, Griffin JD, Groer C, et al. . Human intratumoral therapy: Linking drug properties and tumor transport of drugs in clinical trials. J Control Release. (2020) 326:203–21. doi: 10.1016/j.jconrel.2020.06.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.06.029</ArticleId><ArticleId IdType="pubmed">32673633</ArticleId></ArticleIdList></Reference><Reference><Citation>Metzloff AE, Padilla MS, Gong N, Billingsley MM, Han X, Merolle M, et al. . Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy. Adv Mater. (2024) 36(26):e2313226. doi: 10.1002/adma.202313226</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.202313226</ArticleId><ArticleId IdType="pmc">PMC11209815</ArticleId><ArticleId IdType="pubmed">38419362</ArticleId></ArticleIdList></Reference><Reference><Citation>Han EL, Padilla MS, Palanki R, Kim D, Mrksich K, Li JJ, et al. . Predictive high-throughput platform for dual screening of mRNA lipid nanoparticle blood-brain barrier transfection and crossing. Nano Lett. (2024) 24:1477–86. doi: 10.1021/acs.nanolett.3c03509</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.nanolett.3c03509</ArticleId><ArticleId IdType="pubmed">38259198</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. . Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. (2023) 618:144–50. doi: 10.1038/s41586-023-06063-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06063-y</ArticleId><ArticleId IdType="pmc">PMC10171177</ArticleId><ArticleId IdType="pubmed">37165196</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonderheide R. Q&amp;A: Personalized mRNA vaccine immunogenic against PDAC. Cancer Discovery. (2023) 13:1504. doi: 10.1158/2159-8290.CD-ND2023-0002</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-ND2023-0002</ArticleId><ArticleId IdType="pubmed">37163684</ArticleId></ArticleIdList></Reference><Reference><Citation>Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L, et al. . FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. (2018) 379:2395–406. doi: 10.1056/NEJMoa1809775</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1809775</ArticleId><ArticleId IdType="pubmed">30575490</ArticleId></ArticleIdList></Reference><Reference><Citation>Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. (2019) 16:11–26. doi: 10.1038/s41571-018-0112-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-018-0112-1</ArticleId><ArticleId IdType="pubmed">30341417</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor AA. Gallinger S.Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat Rev Cancer. (2022) 22:131–42. doi: 10.1038/s41568-021-00418-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41568-021-00418-1</ArticleId><ArticleId IdType="pubmed">34789870</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang N, Zhang S, Wang Y. A personalized mRNA vaccine has exhibited potential in the treatment of pancreatic cancer. Holist Integr Oncol. (2023) 2:18. doi: 10.1007/s44178-023-00042-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s44178-023-00042-z</ArticleId><ArticleId IdType="pmc">PMC10248956</ArticleId><ArticleId IdType="pubmed">37323470</ArticleId></ArticleIdList></Reference><Reference><Citation>Balachandran VP, Beatty GL, Dougan SK. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology. (2019) 156:2056–72. doi: 10.1053/j.gastro.2018.12.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.12.038</ArticleId><ArticleId IdType="pmc">PMC6486864</ArticleId><ArticleId IdType="pubmed">30660727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bear AS, Vonderheide RH, O’Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell. (2020) 38:788–802. doi: 10.1016/j.ccell.2020.08</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2020.08</ArticleId><ArticleId IdType="pmc">PMC7738380</ArticleId><ArticleId IdType="pubmed">32946773</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. . Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. (2015) 350:207–11. doi: 10.1126/science.aad0095</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad0095</ArticleId><ArticleId IdType="pmc">PMC5054517</ArticleId><ArticleId IdType="pubmed">26359337</ArticleId></ArticleIdList></Reference><Reference><Citation>Balli D, Rech AJ, Stanger BZ, Vonderheide RH. Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer. Clin Cancer Res. (2017) 23:3129–38. doi: 10.1158/1078-0432.CCR-16-2128</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-16-2128</ArticleId><ArticleId IdType="pubmed">28007776</ArticleId></ArticleIdList></Reference><Reference><Citation>Wartenberg M, Cibin S, Zlobec I, Vassella E, Eppenberger-Castori S, Terracciano L, et al. . Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic/predictive significance. Clin Cancer Res. (2018) 24:4444–54. doi: 10.1158/1078-0432.CCR-17-3401</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-17-3401</ArticleId><ArticleId IdType="pubmed">29661773</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Zhang G, Tang T-Y, Gao X, Liang T-B. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Mil Med Res. (2022) 9:53. doi: 10.1186/s40779-022-00416-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-022-00416-w</ArticleId><ArticleId IdType="pmc">PMC9556149</ArticleId><ArticleId IdType="pubmed">36224645</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackert T, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, Springfeld C, et al. . Locally advanced pancreatic cancer: neoadjuvant therapy with Folfirinox results in resectability in 60% of the patients. Ann Surg. (2016) 264:457–63. doi: 10.1097/SLA.0000000000001850</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000001850</ArticleId><ArticleId IdType="pubmed">27355262</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, et al. . Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol. (2019) 5:1020–7. doi: 10.1001/jamaoncol.2019.0892</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2019.0892</ArticleId><ArticleId IdType="pmc">PMC6547247</ArticleId><ArticleId IdType="pubmed">31145418</ArticleId></ArticleIdList></Reference><Reference><Citation>Aupérin A. Epidemiology of head and neck cancers: an update. Curr Opin Oncol. (2020) 32:178–86. doi: 10.1097/CCO.000000000000629</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCO.000000000000629</ArticleId><ArticleId IdType="pubmed">32209823</ArticleId></ArticleIdList></Reference><Reference><Citation>Syrjänen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol. (2005) 32:59–66. doi: 10.1016/j.jcv.2004.04.11.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2004.04.11.017</ArticleId><ArticleId IdType="pubmed">15753013</ArticleId></ArticleIdList></Reference><Reference><Citation>D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. . Case–control study of human papillomavirus and oropharyngeal cancer. New Engl J Med. (2007) 356:1944–56. doi: 10.1056/NEJMoa065497</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa065497</ArticleId><ArticleId IdType="pubmed">17494927</ArticleId></ArticleIdList></Reference><Reference><Citation>Syrjänen S, Waterboer T, Kero K, Rautava J, Syrjänen K, Grenman S, et al. . Oral human papillomavirus infection in men might contribute to HPV serology. Eur J Clin Microbiol Infect Dis. (2015) 34:237–45. doi: 10.1007/s10096-014-2223-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-014-2223-7</ArticleId><ArticleId IdType="pubmed">25116322</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol. (1995) 146:1355–67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1870892</ArticleId><ArticleId IdType="pubmed">7778675</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao SW, Tsang CM, Lo KW. Epstein–Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci. (2017) 372:20160270. doi: 10.1098/rstb.2016.0270</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2016.0270</ArticleId><ArticleId IdType="pmc">PMC5597737</ArticleId><ArticleId IdType="pubmed">28893937</ArticleId></ArticleIdList></Reference><Reference><Citation>Andre K, Schraub S, Mercier M, Bontemps P. Role of alcohol and tobacco in the aetiology of head and neck cancer: a case-control study in the Doubs region of France. Eur J Cancer B Oral Oncol. (1995) 31:301–9. doi: 10.1016./0964-1955(95)0041-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016./0964-1955(95)0041-0</ArticleId><ArticleId IdType="pubmed">8704646</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha P, Logan HL, Mendenhall WM. Human papillomavirus, smoking, and head and neck cancer. Am J Otolaryngol. (2012) 33:130–6. doi: 10.1016/j.amjoto.2011.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjoto.2011.02.001</ArticleId><ArticleId IdType="pmc">PMC3154993</ArticleId><ArticleId IdType="pubmed">21546122</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao YJ, Goodman JF, Haroun F, Bauman JE. Integrating immunotherapy into multimodal treatment of head and neck cancer. Cancers. (2023) 15:672. doi: 10.3390/cancers15030672</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15030672</ArticleId><ArticleId IdType="pmc">PMC9913370</ArticleId><ArticleId IdType="pubmed">36765627</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington KJ, Burtness, Greil R, Soulières D, Tahara M, de Castro G, et al. . Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Updated results of the phase III KEYNOTE-048 study. J Clin Oncol. (2023) 41:790–802. doi: 10.1200/JCO.21.02508</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.21.02508</ArticleId><ArticleId IdType="pmc">PMC9902012</ArticleId><ArticleId IdType="pubmed">36219809</ArticleId></ArticleIdList></Reference><Reference><Citation>Machiels J-P, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, et al. . Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomized, double-blind, phase 3 trial. Lancet Oncol. (2024) 25:572–5887. doi: 10.1016/S1470-2045(24)00100-1-</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(24)00100-1-</ArticleId><ArticleId IdType="pubmed">38561010</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, et al. . Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. (2018) 119:153–9. doi: 10.1038/s41416-018-01131-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-018-01131-9</ArticleId><ArticleId IdType="pmc">PMC6048158</ArticleId><ArticleId IdType="pubmed">29955135</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritter A, Koirala N, Wieland A, Kaumaya PT, Mitchell DL. Therapeutic cancer vaccines for the management of recurrent and metastatic head and neck cancer: A review. JAMA Otolaryngol Head Neck Surg. (2023) 149:168–76. doi: 10.1001/jamaoto.2022.4264</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2022.4264</ArticleId><ArticleId IdType="pubmed">36580281</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. (2009) . 27:1992–98. doi: 10.1200/JCO.2008.20.2853</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2008.20.2853</ArticleId><ArticleId IdType="pubmed">19289615</ArticleId></ArticleIdList></Reference><Reference><Citation>Caudell JJ, Gillison ML, Maghami E, Spencer S, Pfister DG, Adkins D, et al. . NCCN guidelines® Insights: head and neck cancer, version 1. J Natl Compr Canc Netw. (2022) 20:224–34. doi: 10.6004/jnccn.2022.0016</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2022.0016</ArticleId><ArticleId IdType="pubmed">35276673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. (2005) 14:467–75. doi: 10.1158/1055-9965.EPI-04-0551</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.EPI-04-0551</ArticleId><ArticleId IdType="pubmed">15734974</ArticleId></ArticleIdList></Reference><Reference><Citation>Alizon S, Murall CL, Bravo IG. Why human papillomavirus acute infections matter. Viruses. (2017) 9:293. doi: 10.3390/v9100293</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v9100293</ArticleId><ArticleId IdType="pmc">PMC5691644</ArticleId><ArticleId IdType="pubmed">28994707</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunwitz C, Salomon N, Vascotto F, Selmi A, Bukur T, Diken M, et al. . HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. Oncoimmunology. (2019) . 8:e1629259. doi: 10.1080/2162402X.2019.1629259</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2019.1629259</ArticleId><ArticleId IdType="pmc">PMC6685602</ArticleId><ArticleId IdType="pubmed">31428528</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos da Silva J, Bitencourt Rodrigues K, Formoso Pelegrin G, Silva Sales N, Muramatsu H, de Oliveira Silva M, et al. . Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci Transl Med. (2023) 15:eabn3464. doi: 10.1126/scitranslmed.abn3464</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn3464</ArticleId><ArticleId IdType="pubmed">36867683</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Jiang N, Chen M, Sui B, Liu X. Identification of tumor antigens and immune subtypes in head and neck squamous cell carcinoma for mRNA vaccine development. Front Cell Dev Biol. (2022) 10:1064754. doi: 10.3389/fcell.2022.1064754</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2022.1064754</ArticleId><ArticleId IdType="pmc">PMC9714632</ArticleId><ArticleId IdType="pubmed">36467412</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H-X, Liu T-R, Tu Z-X, Xie C-B, Wen W-P, Sun W. Screening of tumor antigens and construction of immune subtypes for mRNA vaccine development in head and neck squamous cell carcinoma. Biomolecules. (2022) 13:90. doi: 10.3390/biom13010090</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom13010090</ArticleId><ArticleId IdType="pmc">PMC9855883</ArticleId><ArticleId IdType="pubmed">36671475</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogen JP, Grzeschik J, Jakobsen J, Bähre A, Hock B, Holmar H. Treating bladder cancer: engineering of current and next generation antibody-, fusion protein-, mRNA-, cell- and viral-based therapeutics. Front Oncol. (2021) 11:672262. doi: 10.3389/fonc.2021.672262</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.672262</ArticleId><ArticleId IdType="pmc">PMC8191463</ArticleId><ArticleId IdType="pubmed">34123841</ArticleId></ArticleIdList></Reference><Reference><Citation>Luke JJ, Kennedy LC, Sankar N, Menzies AM, van Akkooi ACJ, Gonzalez M, et al. . A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors. J Clin Oncol. (2024) 42:16 suppl, TPS2696-TPS2696.</Citation></Reference><Reference><Citation>Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. . CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro-oncol. (2022) 24:v1–v95. doi: 10.1093/neuonc/noac202</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noac202</ArticleId><ArticleId IdType="pmc">PMC9533228</ArticleId><ArticleId IdType="pubmed">36196752</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargini R, Segura-Collar B, Sánchez-Gómez P. Cellular plasticity and tumor microenvironment in gliomas: the struggle to hit a moving target. Cancers. (2020) 12:1622. doi: 10.3390/cancers12061622</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12061622</ArticleId><ArticleId IdType="pmc">PMC7352204</ArticleId><ArticleId IdType="pubmed">32570988</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson TE, Walker JM, Hambardzumyan D, Brem S, Hatanpaa KJ, Viapiano MS, et al. . Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma. Acta Neuropathol. (2024) 148:5. doi: 10.1007/s00401-024-02761-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-024-02761-7</ArticleId><ArticleId IdType="pmc">PMC11252228</ArticleId><ArticleId IdType="pubmed">39012509</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH. Brain tumor microenvironment and host state: implications for immunotherapy. Clin Cancer Res. (2019) 25:4202–10. doi: 10.1158/1078-0432.CCR-18-1627</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-18-1627</ArticleId><ArticleId IdType="pmc">PMC6635001</ArticleId><ArticleId IdType="pubmed">30804019</ArticleId></ArticleIdList></Reference><Reference><Citation>Nduom EK, Wei J, Yaghi NK, Huang N, Kong L-Y, Gabrusiewicz K, et al. . PD-L1 expression and prognostic impact in glioblastoma. Neuro-oncology. (2015) 18:195–205. doi: 10.1093/neuonc/nov172</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/nov172</ArticleId><ArticleId IdType="pmc">PMC4724183</ArticleId><ArticleId IdType="pubmed">26323609</ArticleId></ArticleIdList></Reference><Reference><Citation>Himes BT, Geiger PA, Ayasoufi K, Bhargav AG, Brown DA, Parney IF. Immunosuppression in glioblastoma: current understanding and therapeutic implications. Front Oncol. (2021) 11:770561. doi: 10.3389/fonc.2021.770561</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.770561</ArticleId><ArticleId IdType="pmc">PMC8581618</ArticleId><ArticleId IdType="pubmed">34778089</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Wang X, Yan Z, Zhang M. Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development. Cancer Med. (2022) 11:2711–26. doi: 10.1002/cam4.46334</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.46334</ArticleId><ArticleId IdType="pmc">PMC9249984</ArticleId><ArticleId IdType="pubmed">35285582</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Wang K, Xiong Y, Zhou L, Yang Y, Chen S, et al. . Identification of tumor antigens and immune subtypes of glioblastoma for mRNA vaccine development. Front Immunol. (2022) 13:773264. doi: 10.3389/fimmu.2022.773264</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.773264</ArticleId><ArticleId IdType="pmc">PMC8847306</ArticleId><ArticleId IdType="pubmed">35185876</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Qin C, Long W, Wang X, Xiao K, Liu Q. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development. J Big Data. (2022) 9:1–25. doi: 10.1186/s40537-022-00643-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40537-022-00643-x</ArticleId><ArticleId IdType="pmc">PMC9281265</ArticleId><ArticleId IdType="pubmed">35855914</ArticleId></ArticleIdList></Reference><Reference><Citation>Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, et al. . TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in Malignant glioma: a randomized phase II trial. Nat Commun. (2024) 15:3882. doi: 10.1038/s41467-024-48073-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-48073-y</ArticleId><ArticleId IdType="pmc">PMC11078958</ArticleId><ArticleId IdType="pubmed">38719809</ArticleId></ArticleIdList></Reference><Reference><Citation>Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, et al. . Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent gliblastoma: A phase 3 prospective externally controlled cohort trial. JAMA Oncol. (2023) 9:112–21. doi: 10.1001/jamaoncol.2022.5370</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2022.5370</ArticleId><ArticleId IdType="pmc">PMC9673026</ArticleId><ArticleId IdType="pubmed">36394838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, et al. . Intrathecal bivalent CAR T cells targeting EGFR and IL13α2 in recurrent glioblastoma: phase 1 trial interim results. Nat Med. (2024) 30:1320–9. doi: 10.1038/s41591-024-02893-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-02893-z</ArticleId><ArticleId IdType="pubmed">38480922</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Rodriguez JL, Yin Y, Logun MT, Zhang L, Yu S, et al. . Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma. Mol Ther. (2024) 31. doi: 10.1016/j.ymthe.2024.07.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2024.07.020</ArticleId><ArticleId IdType="pubmed">39086131</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, et al. . Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med. (2024) 390:1290–98. doi: 10.1056/NEJMoa2314390</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2314390</ArticleId><ArticleId IdType="pmc">PMC11162836</ArticleId><ArticleId IdType="pubmed">38477966</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, Wang D, et al. . Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med. (2024) 30:1001–12. doi: 10.1038/s41591-024-02875-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-02875-1</ArticleId><ArticleId IdType="pmc">PMC11031404</ArticleId><ArticleId IdType="pubmed">38454126</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowenstein PR, Varela ML, Castro MG. Three recent breakthroughs in CAR T cells for the treatment of glioblastoma: Is it the light at the end of the tunnel? Mol Ther. (2024) 32(5):1187–9. doi: 10.1016/j.ymthe.2024.04.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2024.04.018</ArticleId><ArticleId IdType="pmc">PMC11081917</ArticleId><ArticleId IdType="pubmed">38631354</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S, Ba Y, Ji H, Wang F, Du J, Hu S. Recognition of tumor-associated antigens and immune subtypes in glioma for mRNA vaccine development. Front Immunol. (2021) 12:738435. doi: 10.3389/fimmu.2021.738435</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.738435</ArticleId><ArticleId IdType="pmc">PMC8484904</ArticleId><ArticleId IdType="pubmed">34603319</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonderheide RH, Kraynyak KA, Shields AF, McRee AJ, Johnson JM, Sun W, et al. . Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors. J Immunother Cancer. (2021) 9:e003019. doi: 10.1136/jitc-2021-003019</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2021-003019</ArticleId><ArticleId IdType="pmc">PMC8261871</ArticleId><ArticleId IdType="pubmed">34230114</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiller JT, Lowy DR, Frazer IH, Finn OJ, Vilar E, Lyerly HK, et al. . Cancer vaccines. Cancer Cell. (2022) 40:559–64. doi: 10.1016/j.ccell.2022.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2022.05.015</ArticleId><ArticleId IdType="pmc">PMC9190070</ArticleId><ArticleId IdType="pubmed">35700704</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon DA, Brem S, Desai AS, Bagley SJ, Kurz SC, de la Fuente MI, et al. . Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma. J Clin Oncol. (2022) 40:2004. doi: 10.1200/JCO.2022.40.16_suppl.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2022.40.16_suppl.2004</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells. Vitro vivo. J Exp Med. (1996) 184:465–72. doi: 10.1084/jem.184.2.465</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.184.2.465</ArticleId><ArticleId IdType="pmc">PMC2192710</ArticleId><ArticleId IdType="pubmed">8760800</ArticleId></ArticleIdList></Reference><Reference><Citation>Eagles ME, Nassiri F, Badhiwala JH, Suppiah S, Almenawer SA, Zadeh G, et al. . Dendritic cell vaccines for high-grade gliomas. Ther Clin Risk Manag. (2018) 14:1299–313. doi: 10.2147/TCRM.S135865</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S135865</ArticleId><ArticleId IdType="pmc">PMC6067774</ArticleId><ArticleId IdType="pubmed">30100728</ArticleId></ArticleIdList></Reference><Reference><Citation>de Godoy LL, Chawla S, Brem S, Wang S, O’Rourke DM, Nasrallah MP, et al. . Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model. J Neurooncol. (2023) 163:173–83. doi: 10.1007/s11060-023-04324-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11060-023-04324-4</ArticleId><ArticleId IdType="pubmed">37129737</ArticleId></ArticleIdList></Reference><Reference><Citation>Liau LM, Ashkan K, Brem S, Campian J, Trusheim J, Iwamoto F, et al. . Autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent gliblastoma: Survival results from a phase 3 trial. Unpublished data. Neuro-Oncol. (2022) 24:vii66. doi: 10.1093/neuonc/noac209.259</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noac209.259</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster JB, Griffin C, Rokita JL, Stern A, Brimley C, Rathi K, et al. . Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors. J Immunother Cancer. (2022) 10:e004450. doi: 10.1136/jitc-2021-004450</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2021-004450</ArticleId><ArticleId IdType="pmc">PMC9516314</ArticleId><ArticleId IdType="pubmed">36167467</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster MC, Savoldo B, Lau W, Rubinos C, Grover N, Armistead P, et al. . Utility of a safety switch to abrogate CD19 CAR T-cell–associated neurotoxicity. Blood. (2021) 137:3306–09. doi: 10.1182/blood.2021010784</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021010784</ArticleId><ArticleId IdType="pmc">PMC8351894</ArticleId><ArticleId IdType="pubmed">33624095</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalczyk A, Zarychta J, Marsolek A, Zawitkowska J, Lejman M. Chimeric antigen receptor T cell and chimeric antigen receptor NK cell therapy in pediatric and adult high-grade glioma—Recent advances. Cancers. (2024) 16:623. doi: 10.3390/cancers16030623</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers16030623</ArticleId><ArticleId IdType="pmc">PMC10854514</ArticleId><ArticleId IdType="pubmed">38339374</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. . A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent gliobalstoma. Sci Transl Med. (2017) 9:eaaa0984. doi: 10.1126/scitranslmed.aaa0984</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaa0984</ArticleId><ArticleId IdType="pmc">PMC5762203</ArticleId><ArticleId IdType="pubmed">28724573</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Cui Y, Zou L. Treatment advances in high-grade gliomas. Front Oncol. (2024) 14:1287725. doi: 10.3389/fonc.2024.1287725</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2024.1287725</ArticleId><ArticleId IdType="pmc">PMC11039916</ArticleId><ArticleId IdType="pubmed">38660136</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. . Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid Malignancies. Cancer Immunol Res. (2014) 2:112–20. doi: 10.1158/2326-6066.CIR-13-0170</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-13-0170</ArticleId><ArticleId IdType="pmc">PMC3932715</ArticleId><ArticleId IdType="pubmed">24579088</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah PD, Huang AC, Xu X, Orlowski, Amaravadi RK, Schuchter LM, et al. . Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma. Cancer Res Commun. (2023) 3:821–9. doi: 10.1158/2767-9764.CRC-22-0486</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2767-9764.CRC-22-0486</ArticleId><ArticleId IdType="pmc">PMC10167933</ArticleId><ArticleId IdType="pubmed">37377890</ArticleId></ArticleIdList></Reference><Reference><Citation>Montoya M, Gallus M, Phyu S, Haegelin J, de Groot J, Okada H. A roadmap of CAR-T-cell therapy in glioblastoma: challenges and future perspectives. Cells. (2024) 13:726. doi: 10.3390/cells13090726</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells13090726</ArticleId><ArticleId IdType="pmc">PMC11083543</ArticleId><ArticleId IdType="pubmed">38727262</ArticleId></ArticleIdList></Reference><Reference><Citation>Varela ML, Comba A, Faisal SM, Argento A, Franson A, Barissi MN, et al. . Gene therapy for high grade glioma: The clinical experience. Expert Opin Biol Ther. (2023) 23:145–61. doi: 10.1080/14712598.2022.2157718</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14712598.2022.2157718</ArticleId><ArticleId IdType="pmc">PMC9998375</ArticleId><ArticleId IdType="pubmed">36510843</ArticleId></ArticleIdList></Reference><Reference><Citation>Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, et al. . Intratumoral oncolytic herpes virus G47Δ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. (2022) 28:1630–9. doi: 10.1038/s41591-022-01897-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01897-x</ArticleId><ArticleId IdType="pmc">PMC9388376</ArticleId><ArticleId IdType="pubmed">35864254</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Q, Chan KY. An AAV capsid reprogrammed to bind human transferring receptor mediates brain-wide gene delivery. Science. (2024) 384:1220–7. doi: 10.1126/science.adm8386</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adm8386</ArticleId><ArticleId IdType="pubmed">38753766</ArticleId></ArticleIdList></Reference><Reference><Citation>Guterres A, Filho PNS, Moura-Neta V. Breaking barriers: A future perspective on glioblastoma therapy with mRNA-based immunotherapies and oncolytic viruses. Vaccines. (2024) 12:61. doi: 10.3390/vaccines12010061</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12010061</ArticleId><ArticleId IdType="pmc">PMC10818651</ArticleId><ArticleId IdType="pubmed">38250874</ArticleId></ArticleIdList></Reference><Reference><Citation>Guterres A, Abrahim M, da Costa Neves PC. The role of immune subtyping in glioma mRNA vaccine development. Immunotherapy. (2023) 15:1057–72. doi: 10.2217/imt-2023-0027</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/imt-2023-0027</ArticleId><ArticleId IdType="pubmed">37431617</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen P, Aguilar L, Ye X, Reardon D, Bi WL, Peruzzi P, et al. . Phase 1 trial of oncolytic viral immunotherapy with CAN-2409 + valacylovir in combination with nivolumab and standard of care (SOC) in newly diagnosed high-grade glioma (HGG). Neuro-Oncol. (2021) 23:vi52. doi: 10.1093/neuonc/noab196.205</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noab196.205</ArticleId></ArticleIdList></Reference><Reference><Citation>Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Floten J, et al. . Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Transl Med. (2022) 14:eabn2231. doi: 10.1126/scitranslmed.abn2231</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn2231</ArticleId><ArticleId IdType="pmc">PMC9297825</ArticleId><ArticleId IdType="pubmed">35417192</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, et al. . Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med. (2023) 29:1370–78. doi: 10.1038/s41591-023-02347-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02347-y</ArticleId><ArticleId IdType="pmc">PMC10287560</ArticleId><ArticleId IdType="pubmed">37188783</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, He Z, Huang M, Liu T, Wang Y, Xu H, et al. . Vascular niche IL-6 induces alternative macrophage activation in glioblastom through HIF-2α. Nat Commun. (2018) 9:559. doi: 10.1038/s41467-018-03050-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03050-0</ArticleId><ArticleId IdType="pmc">PMC5805734</ArticleId><ArticleId IdType="pubmed">29422647</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, He Z, Duan H, Zhang D, Li J, Yang H, et al. . Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. Nat Commun. (2021) 12:4324. doi: 10.1038/s41467-021-23832-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23832-3</ArticleId><ArticleId IdType="pmc">PMC8187342</ArticleId><ArticleId IdType="pubmed">34103524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamano JB, Lamano JB, Li YD, DiDomenico JD, Choy W, Veliceasa D, et al. . Glioblastoma-derived IL6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth. Clin Cancer Res. (2019) 25:3543–657. doi: 10.1158/1078-0432.CCR-18-2402</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-18-2402</ArticleId><ArticleId IdType="pmc">PMC6571046</ArticleId><ArticleId IdType="pubmed">30824583</ArticleId></ArticleIdList></Reference><Reference><Citation>Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebiel S-E, Daher M, et al. . Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. (2022) 40:509–23. doi: 10.1016/j.ccell.2022.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2022.04.004</ArticleId><ArticleId IdType="pmc">PMC9221568</ArticleId><ArticleId IdType="pubmed">35537412</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson JH, Singh Achrol A, Aghi MK, Bankiewicz, Bexon M, Brem S, et al. . Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial. Neuro-Oncol. (2023) 25:1085–97. doi: 10.1093/neuonc/noac285</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noac285</ArticleId><ArticleId IdType="pmc">PMC10237418</ArticleId><ArticleId IdType="pubmed">36640127</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi V, Yang C, Klippel K, Yegorov O, von Roemeling C, Hoang-Minh L, et al. . mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors. Genome Med. (2024) 16:17. doi: 10.1186/s13073-024-01281-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-024-01281-z</ArticleId><ArticleId IdType="pmc">PMC10809449</ArticleId><ArticleId IdType="pubmed">38268001</ArticleId></ArticleIdList></Reference><Reference><Citation>Akintola OO, Reardon DA. The current landscape of immune checkpoint blockade in glioblastoma. Neurosurg Clin N Am. (2021) 32:2018235–48. doi: 10.1016/j.nec.2020.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nec.2020.12.003</ArticleId><ArticleId IdType="pubmed">33781505</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutnik M, Iakovidis A, Still ME, Moor RS, Melnick K, Yan S, et al. . Advancements in chimeric antigen receptor-expressing T-cell therapy for glioblastoma multiforme: Literature review and future directions. Neurooncol Adv. (2024) 6:1–10. doi: 10.1093/noajnl/vdae025</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/noajnl/vdae025</ArticleId><ArticleId IdType="pmc">PMC10939440</ArticleId><ArticleId IdType="pubmed">38486856</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Jin D, Le SB, Chen D, Sebastian M, Riva A, et al. . Machine learning-directed conversion of glioblastoma cells to dendritic cell-like antigen-presenting cells as cancer immunotherapy. Cancer Immunol Res. (2024). doi: 10.1158/2326-6066.CIR-23-0721</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-23-0721</ArticleId><ArticleId IdType="pubmed">39051633</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Zhao Z, Shin YJ, Yin Y, Raju A, Selvan Vaiyapuri T, et al. . Tumour microenvironment programming by an RNA-RNA binding protein complex creates a druggable vulnerability in IDH-wild-type glioblastoma. Nat Cell Biol. (2024) 26:1003–18. doi: 10.1038/s41556-024-01428-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-024-01428-5</ArticleId><ArticleId IdType="pmc">PMC11178504</ArticleId><ArticleId IdType="pubmed">38858501</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Huang P, Yang R, Deng H. mRNA cancer vaccines: Construction and boosting strategies. ACS Nano. (2023) 17:19550–80. doi: 10.1021/acsnano.3c05635</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.3c05635</ArticleId><ArticleId IdType="pubmed">37819640</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q, Gao H, Tan D, Zhang H, Wang JZ. mRNA cancer vaccines: Advances, trends, and challenges. Acta Pharm Sin B. (2022) 12:2969–89. doi: 10.1016/j.apsb.2022.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2022.03.011</ArticleId><ArticleId IdType="pmc">PMC8942458</ArticleId><ArticleId IdType="pubmed">35345451</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagley SJ, Binder ZA, Lamrani L, Marinari E, Desai AS, MacLean P, et al. . Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase I trial. Nat Cancer. (2024) 5:517–31. doi: 10.1038/s43018-023-00709-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43018-023-00709-6</ArticleId><ArticleId IdType="pubmed">38216766</ArticleId></ArticleIdList></Reference><Reference><Citation>Calimeri T, Marcucci F, Corti A. Overcoming the blood-brain barrier in primary central nervous system lymphoma: a review on new strategies to solve an old problem. Ann Lymph. (2021) 5:20. doi: 10.21037/aol-20-54</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/aol-20-54</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S, Kwak M, Kang J, Cesaire M, Tang K, Robey RW, et al. . Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model. Acta Neuropathol Commun. (2024) 12:9987. doi: 10.1186/s40478-024-01763-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-024-01763-6</ArticleId><ArticleId IdType="pmc">PMC11003129</ArticleId><ArticleId IdType="pubmed">38589905</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard ET, Linde MH, Srivastava S, Klug G, Shabaneh TB, Klug G, et al. . Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell. (2024) 42:119–34. doi: 10.1016/j.ccell.2023.12.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2023.12.011</ArticleId><ArticleId IdType="pmc">PMC10864018</ArticleId><ArticleId IdType="pubmed">38194912</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, Barnum AB, et al. . Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. (2004) 11:711–21. doi: 10.1038/sj.gt.3302213</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gt.3302213</ArticleId><ArticleId IdType="pubmed">14724672</ArticleId></ArticleIdList></Reference><Reference><Citation>Acevedo-Whitehouse K, Bruno R. Potential health risks of mRNA-based vaccine therapy: A hypothesis. Med Hypotheses. (2023) 171:111015. doi: 10.1016/j.mehy.2023.111015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2023.111015</ArticleId><ArticleId IdType="pmc">PMC9876036</ArticleId><ArticleId IdType="pubmed">36718314</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldén M, Olofsson Falla F, Yang D, Barghouth M, Luan C, Rasmussen M, et al. . Intracellular reverse transcription of Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 in vitro in human liver cell line. Curr Issues Mol Biol. (2022) 44:1115–26. doi: 10.3390/cimb44030073</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cimb44030073</ArticleId><ArticleId IdType="pmc">PMC8946961</ArticleId><ArticleId IdType="pubmed">35723296</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Richards A, Barrasa MI, Hughes SH, Young RA, Jaenisch R. Reverse-transcribed SARS-CoV-2RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. Proc Natl Acad Sci USA. (2021) 118:e2105968118. doi: 10.1073/pnas.2105968118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2105968118</ArticleId><ArticleId IdType="pmc">PMC8166107</ArticleId><ArticleId IdType="pubmed">33958444</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ET, Brem S. Taming glioblastoma: targeting angiogenesis. J Clin Oncol. (2007) 25:4705–6. doi: 10.1200/JCO.2007.13.1037</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2007.13.1037</ArticleId><ArticleId IdType="pubmed">17947716</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ET, Brem S. Taming glioblastoma by targeting angiogenesis: 3 years later. J Clin Oncol. (2011) 29:124–6. doi: 10.1200/JCO.2007.13.1037</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2007.13.1037</ArticleId><ArticleId IdType="pubmed">21135277</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotz C, Wagenaar TR, Gieseke F, Bangari DS, Callahan M, Cao H, et al. . Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci Transl Med. (2021) 13:eabc7804. doi: 10.1126/scitranslmed.abc7804</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abc7804</ArticleId><ArticleId IdType="pubmed">34516826</ArticleId></ArticleIdList></Reference><Reference><Citation>Berraondo P, Gomis G, Melero I. The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy. Cancer Cell. (2024) 42:502–4. doi: 10.1016/j.ccell.2024.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2024.02.015</ArticleId><ArticleId IdType="pubmed">38490214</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck JD, Diken M, Suchan M, Streuber M, Diken E, Kolb L, et al. . Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class 1-deficient cancers. Cancer Cell. (2024) 42:1–15. doi: 10.1016/j.ccell.2024.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2024.02.013</ArticleId><ArticleId IdType="pmc">PMC11067690</ArticleId><ArticleId IdType="pubmed">38039965</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Z, Yang H, TGian Y, Liu Z, Sun F, Yang P. An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma. Front Oncol. (2022) 12:975408. doi: 10.3389/fonc.2022.975408</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2022.975408</ArticleId><ArticleId IdType="pmc">PMC9606466</ArticleId><ArticleId IdType="pubmed">36313716</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong S, Liu X, Bi Y, Wang Y, Antony A, Lee D, et al. . Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer. Nat Commun. (2023) 14:6610. doi: 10.1038/s41467-023-42365-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-42365-5</ArticleId><ArticleId IdType="pmc">PMC10587228</ArticleId><ArticleId IdType="pubmed">37857647</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Hu S, Yan N, Popowski KD, Cheng K. Inhalable extracellular vesicle delivery of IL-12mRNA to treat lung cancer and promote systemic immunity. Nat Nanotechnol. (2024) 19:565–75. doi: 10.1038/s41565-023-01580-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41565-023-01580-3</ArticleId><ArticleId IdType="pubmed">38212521</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding L, Li J, Wu C, Yan F, Li X, Zhang S. A self-assembled RNA-triple helix hydrogel drug delivery system targeting triple-negative breast cancer. J Mater Chem B. (2020) 8:3527–33. doi: 10.1039/c9tb01610d</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c9tb01610d</ArticleId><ArticleId IdType="pubmed">31737891</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblum D, Gutkin A, Kedmi R, Ramishetti S, Veiga N, Jacobi AM, et al. . CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv. (2020) 6:eabc9450. doi: 10.1126/sciadv.abc9450</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abc9450</ArticleId><ArticleId IdType="pmc">PMC7673804</ArticleId><ArticleId IdType="pubmed">33208369</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang F, Schrörs B, Löwer M, Tureci Ö, Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discovery. (2022) 21:261–82. doi: 10.1038/s41573-021-00387-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-021-00387-y</ArticleId><ArticleId IdType="pmc">PMC7612664</ArticleId><ArticleId IdType="pubmed">35105974</ArticleId></ArticleIdList></Reference><Reference><Citation>Linette GP, Carreno BM. On the twentieth anniversary of dendritic cell vaccines – Riding the next wave. Cancer Res. (2022) 82:966–8. doi: 10.1158/0008-5472.CAN-21-4440</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-21-4440</ArticleId><ArticleId IdType="pmc">PMC9744103</ArticleId><ArticleId IdType="pubmed">35288731</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell J. Next-generation RNA technologies: making longer-lasting drugs with a broader reach (2023). BioPharma Dive; (Accessed September 4, 2024).</Citation></Reference><Reference><Citation>Dolgin E. Why rings of RNA could be the next blockbuster drug. Nature. (2023) 622:22–4. doi: 10.1038/d41586-023-03058-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-023-03058-7</ArticleId><ArticleId IdType="pubmed">37794271</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P, Hoorn D, Aitha A, Breier D, Peer D. The immunostimulatory nature of mRNA lipid nanoparticles. Adv Drug Delivery Rev. (2024) 205:115175. doi: 10.1016/j.addr.2023.115175</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2023.115175</ArticleId><ArticleId IdType="pubmed">38218350</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallent A. ARPA-H funds two cancer “Manhattan Projects”. Cancer Discovery. (2024) 14:11–2. doi: 10.1158/2159-8290.CD-NB2023-0085</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-NB2023-0085</ArticleId><ArticleId IdType="pubmed">37955532</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub K. mRNA, made famous by COVID vaccine, now enlisted for cancer treatment (usatoday.com) (2023). USA Today; (Accessed 04 September 2024).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>